Urogen Pharma (URGN) News Today $18.59 -1.42 (-7.10%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$18.50 -0.09 (-0.51%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI5 hours ago | tipranks.comUroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beatAugust 7 at 12:52 AM | investing.comUroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beatAugust 7 at 12:52 AM | investing.comUrogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara BancroftAugust 7 at 2:45 PM | tipranks.comUroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial ResultsAugust 7 at 8:00 AM | globenewswire.comUroGen Pharma Q2 2025 Earnings PreviewAugust 6 at 6:14 PM | msn.comD. Boral Capital Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN)August 6 at 9:20 AM | marketbeat.comUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...August 6 at 5:42 AM | finance.yahoo.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High - Should You Buy?August 5 at 10:47 AM | marketbeat.comUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerAugust 5 at 8:00 AM | globenewswire.comPrivium Fund Management B.V. Has $1.19 Million Stock Position in Urogen Pharma (NASDAQ:URGN)August 3, 2025 | marketbeat.comJefferies Financial Group Inc. Lowers Holdings in Urogen Pharma (NASDAQ:URGN)August 1, 2025 | marketbeat.comMark Schoenberg Sells 5,149 Shares of Urogen Pharma (NASDAQ:URGN) StockJuly 31, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) General Counsel Sells $143,971.08 in StockJuly 31, 2025 | marketbeat.comInsider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 5,149 Shares of StockJuly 31, 2025 | insidertrades.comUrogen Pharma (URGN) Projected to Post Earnings on ThursdayJuly 31, 2025 | marketbeat.comUroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025July 29, 2025 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Still a Buy?July 29, 2025 | marketbeat.comUroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical OncologyJuly 29, 2025 | finance.yahoo.comUROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action LawsuitJuly 28, 2025 | globenewswire.comUroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in UrologyJuly 28, 2025 | globenewswire.comARK Investment Management LLC Purchases 45,642 Shares of Urogen Pharma (NASDAQ:URGN)July 27, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Shares Up 9.8% - Still a Buy?July 23, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Reaches New 52-Week High - Time to Buy?July 23, 2025 | marketbeat.comUROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action LawsuitJuly 21, 2025 | globenewswire.comINVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the FirmJuly 21, 2025 | globenewswire.com3 Bullish Biotech Stocks With Explosive Growth Trends (URGN)These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies...July 21, 2025 | marketbeat.comUroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerJuly 21, 2025 | globenewswire.comUROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action LawsuitJuly 19, 2025 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comMigdal Insurance & Financial Holdings Ltd. Increases Stake in Urogen Pharma (NASDAQ:URGN)July 18, 2025 | marketbeat.comURGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class ActionJuly 17, 2025 | globenewswire.comUROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd.July 15, 2025 | globenewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJuly 11, 2025 | globenewswire.comUroGen Pharma Shows Market Leadership With Jump To 81 RS RatingJuly 11, 2025 | msn.comUrogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC WainwrightJuly 8, 2025 | marketbeat.comUroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA ApprovalsJuly 8, 2025 | tipranks.comUrogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral CapitalJuly 7, 2025 | marketbeat.comUroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerJuly 7, 2025 | globenewswire.comUroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder CancerJuly 6, 2025 | msn.comHarel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)July 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJuly 1, 2025 | globenewswire.comURGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for InformationJune 30, 2025 | globenewswire.comURGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 30, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 27, 2025 | prnewswire.comUrogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?June 24, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 23, 2025 | globenewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen†or the “Companyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 23, 2025 | globenewswire.com Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Videos URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.370.39▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼137▲URGN Articles Average Week Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SpringWorks Therapeutics News Today Protagonist Therapeutics News Today Ascentage Pharma Group International News Today MoonLake Immunotherapeutics News Today HUTCHMED News Today Immunovant News Today Kymera Therapeutics News Today Alvotech News Today MorphoSys News Today Crinetics Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.